Literature DB >> 28949101

Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.

Josep Lupón1,2,3, Joanne Simpson4, John J V McMurray4, Marta de Antonio1,2, Joan Vila5,6, Isaac Subirana5,6, Jaume Barallat7, Pedro Moliner1, Mar Domingo1, Elisabet Zamora1,2,3, Antoni Bayes-Genis1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28949101     DOI： 10.1002/ejhf.949

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  7 in total

1.  Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score.

Authors:  Christopher O'Connor; Mona Fiuzat; Hillary Mulder; Adrian Coles; Tariq Ahmad; Justin A Ezekowitz; Kirkwood F Adams; Ileana L Piña; Kevin J Anstrom; Lawton S Cooper; Daniel B Mark; David J Whellan; James L Januzzi; Eric S Leifer; G Michael Felker
Journal:  Eur J Heart Fail       Date:  2019-03-27       Impact factor: 15.534

Review 2.  Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future.

Authors:  Farah Omran; Ioannis Kyrou; Faizel Osman; Ven Gee Lim; Harpal Singh Randeva; Kamaljit Chatha
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

Review 3.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

4.  Clinical Utility and Validation of the Krakow DCM Risk Score-A Prognostic Model Dedicated to Dilated Cardiomyopathy.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska-Małocha; Matylda Gliniak; Jan Robak; Monika Kaciczak; Przemysław Leszek; Małgorzata Celińska-Spodar; Marcin Dziewięcki; Paweł Rubiś
Journal:  J Pers Med       Date:  2022-02-08

5.  Mortality Risk Prediction Dynamics After Heart Failure Treatment Optimization: Repeat Risk Assessment Using Online Risk Calculators.

Authors:  Pau Codina; Elisabet Zamora; Wayne C Levy; Elena Revuelta-López; Andrea Borrellas; Giosafat Spitaleri; Germán Cediel; María Ruiz-Cueto; Elena Cañedo; Evelyn Santiago-Vacas; Mar Domingo; David Buchaca; Isaac Subirana; Javier Santesmases; Rafael de la Espriella; Julio Nuñez; Josep Lupón; Antoni Bayes-Genis
Journal:  Front Cardiovasc Med       Date:  2022-04-12

6.  Incremental prognostic value of lung ultrasound on contemporary heart failure risk scores.

Authors:  Alba Maestro-Benedicto; Mercedes Rivas-Lasarte; Juan Fernández-Martínez; Laura López-López; Eduard Solé-González; Vicens Brossa; Sonia Mirabet; Eulàlia Roig; Juan Cinca; Jesús Álvarez-García; Alessandro Sionis
Journal:  Front Physiol       Date:  2022-09-14       Impact factor: 4.755

7.  Mortality risk in dilated cardiomyopathy: the accuracy of heart failure prognostic models and dilated cardiomyopathy-tailored prognostic model.

Authors:  Ewa Dziewięcka; Matylda Gliniak; Mateusz Winiarczyk; Arman Karapetyan; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Marcin Dziewięcki; Piotr Podolec; Paweł Rubiś
Journal:  ESC Heart Fail       Date:  2020-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.